Marker Therapeutics Says European Medicines Agency Granted Orphan Drug Designation For MT-401 For Treatment Of AML Patients
Portfolio Pulse from Benzinga Newsdesk
Marker Therapeutics announced that its product candidate, MT-401, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the treatment of patients with acute myeloid leukemia (AML).
July 10, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marker Therapeutics' MT-401 has received Orphan Drug Designation from the EMA, potentially opening up a new market for the treatment of AML.
The Orphan Drug Designation by the EMA is a significant regulatory milestone for Marker Therapeutics. This could potentially open up a new market for the company's MT-401 in the treatment of AML, which could positively impact the company's revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100